SMTL ID : 4c4j.1

Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.50 Å

Oligo State

monomer

Ligands

1 x X21: tert-butyl 6-{[2-chloro-4-(1-methyl-1H-imidazol-5-yl)phenyl]amino}-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(Non-covalent)

X21.1: 19 residues within 4Å: Chain A: I.36, G.37, V.44, Q.46, A.56, K.58, E.76, M.107, E.108, C.109, G.110, N.111, I.112, D.113, S.116, L.159, I.168, M.176, P.178 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:I.36, A:A.56, A:M.176 Hydrogen bonds: A:K.58, A:G.110, A:G.110, A:S.116 Halogen bonds: A:Q.46

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Naud, S. et al., Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3, 2-C]Pyridine Inhibitors of the Mitotic Kinase Monopolar Spindle 1 (Mps1). J.Med.Chem. (2013)

Release Date

2013-12-04

Peptides

DUAL SPECIFICITY PROTEIN KINASE TTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

DUAL SPECIFICITY PROTEIN KINASE TTK

Related Entries With Identical Sequence